Cheng Z Liu, 52New York, NY

6346101, Feb 12, 2002

Jun 4, 1997

08/887196

Robert R. Alfano - Bronx NY
Cheng Hui Liu - Flushing NY

Research Foundation of City College of New York - New York NY

A61B 1818

606 15, 606 1, 606 10, 606 13, 606 17, 604 19, 604 20, 128898

A photon-mediated technique for introducing biological materials into cells and/or cellular components. The technique may be used to introduce nucleic acids, such as DNA and RNA, proteins or other biological materials into mammalian cells (as well as into other animal and plant cells), which materials may then flow into the nuclei of the cells. The technique uses picosecond or femtosecond light pulses propagating in the UV, visible and near infrared wavelength regions with powers on the order of 1Ã10 W/cm. In practice, the desired biological materials are coated on the end of the inner core of a single mode fiber or the ring core of a fiber in a fiber array. Each fiber is sized to correspond to one cell, with the core size ranging from 2 to 10, and the cladding ranging from 10 to 30. The laser pulse travels through a fiber core which is coated with the materials and ablates a portion of a targeted cell or cellular component membrane. In addition, as the laser pulse exits the fiber, it imparts energy and momentum to the materials applied to the end of the fiber.

5261410, Nov 16, 1993

Feb 7, 1991

7/651449

Robert R. Alfano - Bronx NY
Cheng H. Liu - Flushing NY
Wenling S. Glassman - Bronx NY

A61B 600

128664

A method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue. The present method is based on the discovery that, when irradiated with a beam of infrared, monochromatic light, malignant tumor tissue, benign tumor tissue, and normal or benign tissue produce distinguishable Raman spectra. For human breast tissue, some salient differences in the respective Raman spectra are the presence of four Raman bands at a Raman shift of about 1078, 1300, 1445, and 1651 cm. sup. -1 for normal or benign tissue, the presence of three Raman bands at a Raman shift of about 1240, 1445, and 1659 cm. sup. -1 for benign tumor tissue, and the presence of two Raman bands at a Raman shift of about 1445 and 1651 cm. sup. -1 for malignant tumor tissue. In addition, it was discovered that for human breast tissue the ratio of intensities of the Raman bands at a Raman shift of about 1445 and 1659 cm. sup.

5293872, Mar 15, 1994

Apr 3, 1991

7/678637

Robert R. Alfano - Bronx NY
Cheng H. Liu - Flushing NY

A61B 600

128664

A method for distinguishing between calcified atherosclerotic tissue and either fibrous atherosclerotic tissue or normal cardiovascular tissue. The present method is based on the discovery that, when irradiated with a beam of monochromatic infrared light, calcified atherosclerotic human aortic tissue produces a Fourier Transform Raman spectrum which is distinguishable from analagous spectra obtained from fibrous atherosclerotic human aortic tissue and normal human aortic tissue. Some salient differences in the respective Raman spectra are the presence of five Raman bands at Raman shifts of 957, 1071, 1262-1300, 1445, and 1659 cm. sup. -1 (. +-. 4 cm. sup. -1 for all shifts) for the calcified tissue as compared to three Raman bands at Raman shifts of 1247-1270, 1453 and 1659 cm. sup. -1 (. +-. 4 cm. sup. -1 for all shifts) for the fibrous tissue and three Raman bands at Raman shifts of 1247-1270, 1449 and 1651 cm. sup. -1 (. +-. 4 cm. sup. -1 for all shifts) for the normal tissue.

5656810, Aug 12, 1997

Nov 22, 1993

8/155450

Robert R. Alfano - Bronx NY
Cheng H. Liu - Flushing NY

The Research Foundation of City College of New York

G01N 2164

250301

A method and apparatus for evaluating the composition of an oil sample. The method and apparatus are premised on the discovery that spectral differences can be observed in the luminescence, excitation, light scattering and absorption spectra in the near UV, visible and near IR regions for various crude oil components, such as asphaltenes, deasphalted crude oil and organic solid residues. Accordingly, in one preferred embodiment the method comprises illuminating an oil sample with light of a suitable excitation wavelength, measuring the resultant fluorescence therefrom and comparing the resultant fluorescence to appropriate standards derived from known components of crude oil.

5635402, Jun 3, 1997

Apr 29, 1994

8/236861

Robert R. Alfano - Bronx NY
Cheng H. Liu - Flushing NY
Wei L. Sha - New York NY
Yury Budansky - Oakland NJ

G01N 2164
G01N 3352

436 63

A technique for determining whether a cell is malignant as opposed to non-malignant using extrinsic fluorescence spectroscopy. The technique is premised on the principle that certain fluorescent dyes preferentially stain malignant cells as opposed to non-malignant cells. Accordingly, by exposing a cell to the fluorescent dye, irradiating the cell with light of such a wavelength as to cause the dye to fluoresce, measuring the intensity of fluorescence at a wavelength indicative of fluorescence of the dye, and comparing the fluorescence intensity to standards obtained from malignant cells and non-malignant cells, it is possible for one to accurately classify the cell as being either malignant or non-malignant. The present invention also relates to an automated system which applies the principles of the aforementioned technique to depict the spatial distribution of cells within an area of a Pap smear-type sample and to characterize each of the cells as being malignant or non-malignant.

2020011, Apr 16, 2020

Oct 28, 2019

16/665708

- New York NY, US
- Emeryville CA, US
Andres Lopez-Albaitero - New York NY, US
Cheng Liu - Emeryville CA, US
Su Yan - State College PA, US
Jingyi Xiang - Walnut Creek CA, US
Hong Liu - El Sobrante CA, US

C07K 16/46
G01N 33/68
C07K 16/28
C07K 16/08

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

2018025, Sep 13, 2018

Jun 9, 2016

15/735133

- New York NY, US
- Emeryville CA, US
Andres Lopez-Albaitero - New York NY, US
Cheng Liu - Emeryville CA, US
Su Yan - State College PA, US
Jingyi Xiang - Walnut Creek CA, US
Hong Liu - El Sobrante CA, US

C07K 16/46
C07K 16/08
C07K 16/28
G01N 33/68

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

2016028, Sep 29, 2016

Nov 7, 2014

15/034782

- New York NY, US
- Emeryville CA, US
Tao Dao - New York NY, US
Su Yan - State College PA, US
Cheng Liu - Oakland CA, US

C07K 16/32
C07K 16/28

Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-γ) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc* (NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis. Also provided are methods for stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating effector T cells and/or memory T cells against a first tumor antigen and/or against a second tumor antigen using the bi-specific antibodies described herein.